Company news

Share this article:

Drug developer Depomed said it would cut about 25% of its workforce after its lead drug candidate, Gabapentin GR, failed in a late-stage clinical trial. The company had 105 full-time employees as of Dec. 31, according to a filing with the Securities and Exchange Commission.


Forest Laboratories and Microbia announced that they have entered into co-development and co-marketing deal valued at up to $330 million for Microbia's first-in-class compound linaclotide, currently being investigated for the treatment of constipation-predominant irritable bowel syndrome, chronic constipation and other gastrointestinal disorders.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.